Program
Torsemide
Also written as “Torasemide tablet 10 mg”, “torasemide” and “torsemide”.
Its studies are mostly in Heart Failure · Edema · Body Weight Changes · Hypertension · Diabetes Mellitus, Type 2, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sarfez Pharmaceuticals | 40 open or running | phase 4since Nov 24, 2024 | Apr 17, 2018 | none ahead |
| Ferrer Internacional | 20 open or running | phase 4since Jun 6, 2006 | Jun 6, 2006 | none ahead |
| Hikma Pharmaceuticals | 20 open or running | no phasesince Jan 15, 2008 | Jan 15, 2008 | none ahead |
| Par Health | 20 open or running | phase 1since Apr 1, 2008 | Apr 1, 2008 | none ahead |
| Menarini Group | 11 open or running | phase 1since Sep 10, 2025 | Sep 10, 2025 | none ahead |
Also a collaborator on its studies: anapharm.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 6, 2006First study: phase 4 study in HypertensionNew to Ferrer InternacionalFerrer Internacional · NCT00334386 · 388 enrolled
- Dec 11, 2006Phase 4 study in Heart FailureFerrer Internacional · NCT00409942 · 142 enrolled · Spain
- Jan 15, 2008Hikma Pharmaceuticals's first studies: 2 no phase studies in EdemaNew to Hikma PharmaceuticalsHikma Pharmaceuticals · NCT00602615, NCT00602303
- Apr 1, 2008Par Health's first studies: 2 phase 1 studiesNew to Par HealthPar Health · NCT00654043, NCT00653549
- Apr 17, 2018Sarfez Pharmaceuticals's first study: phase 1 study in Body Weight ChangesNew to Sarfez PharmaceuticalsSarfez Pharmaceuticals · NCT03509545 · 20 enrolled · India
- Nov 24, 2024Phase 4 study in Heart FailureSarfez Pharmaceuticals · NCT06708611 · United States
- Jun 3, 20252 phase 3 studiesSarfez Pharmaceuticals · NCT07015671, NCT07046975
- Sep 10, 2025Menarini Group's first study: phase 1 study in Healthy Adult Male and Female VolunteersNew to Menarini GroupMenarini Group · NCT07201584 · 26 planned · Kazakhstan
TargetBeta
“Sodium-(potassium)-chloride cotransporter 2 inhibitor”ChEMBL 37, by rule
Other programs on SLC12A1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Furosemiderule | Boehringer Ingelheim | phase 4 | 27 |
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07201584Healthy Adult Male and Female Volunteers · Kazakhstan | 1 | Recruiting | Menarini Group | Dec 30, 2025 | 26 |
| NCT07046975Bioavailability Heathy Volunteers · United States | 3 | Completed | Sarfez Pharmaceuticals | Feb 28, 2026 | 24 |
| NCT07015671Bioequivalence Study in Healthy Subjects · United States | 3 | Completed | Sarfez Pharmaceuticals | Dec 30, 2025 | 24 |
| NCT06708611Heart Failure · United States | 4 | Withdrawn | Sarfez Pharmaceuticals | Mar 25, 2025 | 0 |
| NCT03509545Body Weight Changes · India | 1 | Terminated | Sarfez Pharmaceuticals | Jun 30, 2022 | 20 |
| NCT00654043Lecithin Cholesterol Acyltransferase Deficiency | 1 | Completed | Par Health | May 2001 | 24 |
| NCT00653549Fasting | 1 | Completed | Par Health | May 2001 | 26 |
| NCT00602615Edema · United States | – | Completed | Hikma Pharmaceuticals | Sep 2003 | 28 |
| NCT00602303Edema · United States | – | Completed | Hikma Pharmaceuticals | Sep 2003 | 28 |
| NCT00409942Heart Failure · Spain | 4 | Completed | Ferrer Internacional | Jun 2009 | 142 |
| NCT00334386Hypertension | 4 | Completed | Ferrer Internacional | 388 |
How it is read
Names in the registry
- “Torsemide”, 4 entries
- “Torasemide tablet 10 mg”, 2 entries
- “torasemide”, 2 entries
- “torsemide”, 1 entry
- “CHF Patients: ER Torsemide 40 mg”, 1 entry
Conditions, from the studies’ own filings
- Heart Failure, 2 studies
- Edema, 2 studies
- Body Weight Changes, 1 study
- Hypertension, 1 study
- Diabetes Mellitus, Type 2, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.